NeoGenomics, Inc.(NEO)Earnings, Financials & Key RatiosNeoGenomics, Inc. (NEO) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to generate consistent free cash flow, evidenced by a -7.0% FCF margin in 2026Q1, combined with persistent net losses, suggests significant execution risk for investors.
NeoGenomics, Inc. (NEO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
NeoGenomics, Inc. (NEO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.01vs $0.01+73.0% | $187Mvs $185M+1.2% |
| Q1 2026 | Feb 17, 2026 | $0.06vs $0.04+50.0% | $190Mvs $188M+0.9% |
| Q4 2025 | Oct 28, 2025 | $0.03vs $0.02+50.0% | $188Mvs $188M-0.2% |
| Q3 2025 | Jul 29, 2025 | $0.03vs $0.03+0.0% | $181Mvs $184M-1.4% |
Recent stock market news and headlines for NeoGenomics, Inc. (NEO)
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.
Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S. development, where NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations CALABASAS, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, the Company's lead candidate, an intranasally administered formulation of purified perillyl alcohol designed for non-invasive nose-to-brain delivery.
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neo Performance Materials Inc. (NEO:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Key metrics vs top competitors for NeoGenomics, Inc. (NEO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.50 | $377.42M | -3.45 | 10.11% | -14.85% | -12.42% | — | |
| $53.01 | $2.76B | 135.92 | — | 33.7% | 22.86% | — | |
| $28.31 | $1.46B | -70.78 | 13.79% | -1.98% | -2.61% | — | |
| $281.27 | $40.28B | -185.05 | 35.9% | -9.05% | -15.13% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $283.86 | $23.36B | 27.14 | 7.25% | 6.66% | 10.89% | — |
NeoGenomics, Inc. (NEO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NeoGenomics, Inc. (NEO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 28, 2026·SEC
Feb 17, 2026·SEC
Jan 12, 2026·SEC
Get notified when NEO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NeoGenomics, Inc. (NEO) stock FAQ — growth, dividends, profitability & financials explained
NeoGenomics, Inc. (NEO) reported $746.0M in revenue for fiscal year 2025. This represents a 295447% increase from $0.3M in 2000.
NeoGenomics, Inc. (NEO) grew revenue by 10.1% over the past year. This is steady growth.
NeoGenomics, Inc. (NEO) reported a net loss of $99.2M for fiscal year 2025.
NeoGenomics, Inc. (NEO) has a return on equity (ROE) of -12.4%. Negative ROE indicates the company is unprofitable.
NeoGenomics, Inc. (NEO) had negative free cash flow of $5.1M in fiscal year 2025, likely due to heavy capital investments.
